<DOC>
	<DOCNO>NCT01402154</DOCNO>
	<brief_summary>The primary objective study evaluate predictive value ( term remission ) new technique detect circulating , functional , prostate cell among patient localize adenocarcinoma prostate , prior treatment .</brief_summary>
	<brief_title>EPISPOT Detection Circulating Prostate Cells Among Adenocarcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>The patient must give his/her inform sign consent The patient must insure beneficiary health insurance plan Histologically prove presence prostate adenocarcinoma Localized disease digital rectal examination Cancer without extension Acceptance curative treatment patient The patient participate another study The patient exclusion period determine previous study The patient judicial protection , tutorship curatorship The patient refuse sign consent It impossible correctly inform patient The patient take hormonemodifying treatment Patient take adrogenic supplement</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>